Credit Suisse Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Tiago Fauth maintains an Outperform rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $63 to $62.
August 11, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Credit Suisse maintains an Outperform rating on Ventyx Biosciences but lowers the price target from $63 to $62.
The news is directly related to Ventyx Biosciences (VTYX). While the Outperform rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact is likely to be neutral as the decrease in the price target is minimal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100